Recent News

• 05.14.2025 - Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability
• 05.07.2025 - Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025
• 05.05.2025 - Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®
• 03.24.2025 - Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders
• 03.19.2025 - Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas
• 03.05.2025 - Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth
• 03.05.2025 - Kamada Declares Special Cash Dividend of $0.20 Per Share

Recent Filings

• 05.14.2025 - EX-99.1 EX-99.1
• 05.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.07.2025 - EX-99.1 EX-99.1
• 05.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.05.2025 - EX-99.1 EX-99.1
• 03.24.2025 - EX-99.1 EX-99.1
• 03.24.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.19.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.19.2025 - EX-99.1 EX-99.1